The FDA is kicking off May with three target action dates and three advisory committee meetings, including one for a high-profile investigational gene therapy.
Tag Archive for: Fabry disease
The FDA put 4D Molecular Therapeutics’ gene therapy program, 4D-310, on clinical hold, the company announced February 2.
Through its Alexion subsidiary, AstraZeneca is acquiring Lexington, Mass.-based LogicBio Therapeutics in a deal worth $68 million. The deal bolsters AstraZeneca’s efforts in genomics and rare diseases.